Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How To Navigate the American Healthcare System

This week on I Don’t Care, Host Kevin Stevenson sits down with an author that has made it his mission to teach people how to navigate the healthcare system, arming patients with the proactive education needed to shop around for the best healthcare and insurance options while preventing unnecessary or overly costly treatments. After 28…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

This week on I Don’t Care, Host Kevin Stevenson sits down with an author that has made it his mission to teach people how to navigate the healthcare system, arming patients with the proactive education needed to shop around for the best healthcare and insurance options while preventing unnecessary or overly costly treatments.

After 28 years working within the American healthcare system, Dr. David Wilcox has seen enough in the medical field to realize that it truly is a “business” as opposed to the kind-hearted healing service that most people might imagine it to be.

His new book reveals some unsettling facts and offers information, facts, and tips for patients and family members who are navigating through this morass. Along with revealing what he has learned over the last 28 years, he also offers helpful hints on how patients can avoid becoming victims of an industry that seems intent on profiting at all costs rather than providing quality care for its clients. 

 This book is a wake-up call for all of us who are taxpayers, or soon will be. It provides the tools needed to avoid being caught in this system that unfairly targets certain groups and takes away our rights as consumers without providing necessary care.

Dr. David Wilcox wants people aware so they can protect themselves from getting netted into an unfair spiral – having their lives negatively impacted by high premiums with no options; denied coverage because you have pre-cancerous cells or “preexisting” conditions; over treated until you’re a candidate for hospice rather than making more money for the same incompetent doctors who read MRI’s upside down and prescribe meds that most people wouldn’t dose their dogs with.

He also goes into what most of us wish we had known before our experience with US healthcare, including how to deal with a surgeon who is drunk or high on the job, or why some doctors and hospitals just don’t care.

More Like This Story:

From an Idea to Billion Dollar Company: How a Doctor Lobbied DC for HSAs

Does the Insurance Model of the Future Exclude A Traditional Health Insurance Carrier

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512